Table 2.
Study-specific characteristics
| Author, year | N Pts | Age | F/u (mo) | N TR (%) | Baseline PS | Baseline SD | 1mo PS | 3mo PS | 3mo SD | N ≥ G3 tox (%) | N < G3 tox (%) | FUS system |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Namba, 2019 [13] | 10 | 69 | 3 | 8 (80) | 6 | 2.7 | 3 | 2 | 4.1* | InSightec | ||
| Tsai, 2019 [14] | 31 | 60 | 3 | 26 (84) | 5.6 | 1.8 | 0 (0) | 4 (12.9) | InSightec | |||
| Wang B., 2019 [15] | 30 | 4.3 | 3 | 26 (87) | 6.6 | 2.4 | 3.4 | 1.8 | 0.96 | 0 (0) | 8 (2.7) | InSightec |
| Giles, 2019 [16] | 9 | 52.6 | 3 | 6 (67) | 7.3 | 1.4 | 2.5 | 1.5 | 2.2 | 0 (0) | 2 (2.2) | Profound Medical |
| Dababou, 2019 [42] | 140 | 12 | 109 (78) | N/A | ||||||||
| Marrocchio, 2019 [43] | 11 | 0 (0) | 0 (0) | N/A | ||||||||
| Bertrand, 2018 [17] | 17 | 61 | 1 | 14 (82) | 7.5 | 1.33 | 1.9 | InSightec | ||||
| Wang S., 2018 [18] | 21 | 3 | 7.7 | 1.6 | 3.9 | 3.7 | 2.7 | N/A | ||||
| Chen Z., 2018 [19] | 26 | 60 | 12 | 6.7 | 1.5 | 4 | 4.8 | 1.1 | InSightec | |||
| Harding, 2018 [20] | 18 | 57 | 3 | 13 (72) | 7 | 1 | 0 (0) | 0 (0) | Philips | |||
| Xiong, 2018 [22] | 14 | 3 | 6.5 | 4 | 5.25 | 2.5 | 4.75 | 1 (7.1) | 5 (3.6) | N/A | ||
| Lee H., 2017 [21] | 21 | 59 | 3 | 16 (76) | 6.57 | 1.6 | 2 | 1 | 1.4* | 0 (0) | 2 (9.5) | InSightec |
| Bazzocchi, 2017 | 11 | 56 | 3 | 3.8 | 2.8 | 1.8 | 2.3 | 0 (0) | 0 (0) | N/A | ||
| Chan M., 2017 [24] | 6 | 68.5 | 1 | 6 (100) | 2 | 0 (0) | 0 (0) | Philips | ||||
| Anzidei, 2016 [25] | 23 | 63.6 | 6 | 22 (96) | 7.09 | 1.8 | 2.65 | 1.04 | 1.91 | 0 (0) | 0 (0) | InSightec |
| Wang Q., 2016 [26] | 71 | 3 | 6.7 | 1.82 | 4 | 3.7 | 2.81 | N/A | ||||
| Gu, 2015 [27] | 23 | 6 | 1.5 | 3.1 | 2.2 | 1 | 0 (0) | 4 (17.4) | InSightec | |||
| Joo, 2015 [28] | 5 | 60 | 12 | 5.92 | 1.28 | 2.92 | 0.75 | 1 | 0 (0) | 1 (20.0) | InSightec | |
| Chen L., 2014 [29] | 7 | 3 | 8 | 1.1 | 3 | 3.4 | 1.5 | 0 (0) | 0 (0) | N/A | ||
| Huisman, 2014 [30] | 11 | 60 | 1 | 7 (64) | 7.54 | 3.75 | 3.82 | 0 (0) | 2 (18.2) | Philips | ||
| Hurwitz, 2014 [31] | 112 | 61.7 | 3 | 72 (64) | 7 | 3.1 | 3.3 | 3.3 | 3.4* | 3 (2.7) | 11 (9.8) | InSightec |
| Pfeffer, 2014 [32] | 22 | 69 | 3 | 16 (73) | 0 (0) | 0 (0) | N/A | |||||
| Turkevich, 2014 [33] | 32 | 57 | 3 | 32 (100) | 6.8 | 1.9 | 1.1 | 0 (0) | 0 (0) | InSightec | ||
| Zaccagna, 2014 | 72 | 62 | 6 | 63 (88) | 6 | 6.3 | 2 | 6.3* | 0 (0) | 0 (0) | InSightec | |
| Boni, 2013 [44] | 11 | 8 (73) | N/A | |||||||||
| Napoli, 2013 [35] | 18 | 63 | 3 | 16 (89) | 7.1 | 2.08 | 2.5 | 1 | 1.1 | 0 (0) | 0 (0) | InSightec |
| Pfeffer, 2013 | 17 | 59 | 3 | 13 (76) | 7.6 | 3.1 | 2.7 | 0 (0) | 0 (0) | N/A | ||
| Noce, 2013 [45] | 36 | 60.3 | 3 | 0 (0) | 0 (0) | InSightec | ||||||
| Meyer, 2013 | 115 | 3 (2.6) | 1 (0.9) | N/A | ||||||||
| Catane, 2012 [38] | 93 | 3 | 6.9 | 3.3 | 2.6 | 0 (0) | 6 (6.5) | N/A | ||||
| Liberman, 2009 [39] | 25 | 61 | 3 | 18 (72) | 5.9 | 0.8 | 2.3 | 1.8 | 1.4* | 0 (0) | 0 (0) | InSightec |
| Gianfelice, 2008 [40] | 11 | 59 | 3 | 11 (100) | 6.27 | 1.73 | 1.3 | 0.5 | 0.54 | 0 (0) | 0 (0) | InSightec |
| Catane, 2007 [41] | 13 | 6 | 5.5 | 1.7 | 1.2 | 0 (0) | 1 (7.7) | InSightec |
*Estimated SD
PS, pain score, TR, treatment response